HRP20150360T1 - Poksvirusni onkolitiäśki vektori - Google Patents

Poksvirusni onkolitiäśki vektori Download PDF

Info

Publication number
HRP20150360T1
HRP20150360T1 HRP20150360TT HRP20150360T HRP20150360T1 HR P20150360 T1 HRP20150360 T1 HR P20150360T1 HR P20150360T T HRP20150360T T HR P20150360TT HR P20150360 T HRP20150360 T HR P20150360T HR P20150360 T1 HRP20150360 T1 HR P20150360T1
Authority
HR
Croatia
Prior art keywords
poxvirus
pharmaceutical preparation
accordance
treatment
intended
Prior art date
Application number
HRP20150360TT
Other languages
English (en)
Croatian (hr)
Inventor
Philippe Erbs
Johann Foloppe
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of HRP20150360T1 publication Critical patent/HRP20150360T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
HRP20150360TT 2007-11-19 2008-11-17 Poksvirusni onkolitiäśki vektori HRP20150360T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301556 2007-11-19
PCT/EP2008/009721 WO2009065547A2 (en) 2007-11-19 2008-11-17 Poxviral oncolytic vectors
EP08851361.9A EP2212423B1 (en) 2007-11-19 2008-11-17 Poxviral oncolytic vectors

Publications (1)

Publication Number Publication Date
HRP20150360T1 true HRP20150360T1 (hr) 2015-05-08

Family

ID=40548531

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150360TT HRP20150360T1 (hr) 2007-11-19 2008-11-17 Poksvirusni onkolitiäśki vektori

Country Status (21)

Country Link
US (1) US9180150B2 (enExample)
EP (1) EP2212423B1 (enExample)
JP (1) JP5710262B2 (enExample)
KR (1) KR101542275B1 (enExample)
CN (1) CN101868546B (enExample)
AU (1) AU2008328258B2 (enExample)
BR (1) BRPI0820578A2 (enExample)
CA (1) CA2705873C (enExample)
CO (1) CO6210761A2 (enExample)
CR (1) CR11520A (enExample)
DK (1) DK2212423T3 (enExample)
EC (1) ECSP10010287A (enExample)
ES (1) ES2535633T3 (enExample)
HR (1) HRP20150360T1 (enExample)
IL (1) IL204539A (enExample)
MX (1) MX2010005273A (enExample)
NZ (1) NZ584201A (enExample)
PL (1) PL2212423T3 (enExample)
RU (2) RU2557312C2 (enExample)
WO (1) WO2009065547A2 (enExample)
ZA (1) ZA201004286B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744294A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
EP2452194B1 (en) 2009-07-10 2015-11-11 Transgene SA Biomarker for selecting patients and related methods
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
ES2833425T3 (es) * 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
US10517943B2 (en) 2014-12-01 2019-12-31 Transgene S.A. Stable liquid vaccinia virus formulations
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
KR20250067190A (ko) * 2016-08-09 2025-05-14 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CN111163803B (zh) * 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
JP2021511060A (ja) * 2018-01-26 2021-05-06 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CA3124773A1 (en) 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
EP1367128A1 (en) * 1991-03-07 2003-12-03 Connaught Technology Corporation Genetically engineered vaccine strain
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU5446700A (en) * 1999-05-28 2000-12-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
MXPA05013879A (es) * 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
DK2212345T3 (en) * 2007-11-19 2016-03-21 Transgene Sa Oncolytic poxvirus vectors

Also Published As

Publication number Publication date
CN101868546B (zh) 2013-06-05
CA2705873C (en) 2012-06-12
AU2008328258A1 (en) 2009-05-28
KR101542275B1 (ko) 2015-08-06
DK2212423T3 (en) 2015-03-16
RU2557312C2 (ru) 2015-07-20
IL204539A0 (en) 2010-11-30
WO2009065547A3 (en) 2009-07-09
AU2008328258A2 (en) 2010-05-13
CO6210761A2 (es) 2010-10-20
RU2013129678A (ru) 2015-01-10
NZ584201A (en) 2012-06-29
ZA201004286B (en) 2011-04-28
WO2009065547A2 (en) 2009-05-28
RU2010124613A (ru) 2011-12-27
US20110044948A1 (en) 2011-02-24
MX2010005273A (es) 2010-08-31
KR20100094468A (ko) 2010-08-26
JP2011504105A (ja) 2011-02-03
RU2508401C2 (ru) 2014-02-27
US9180150B2 (en) 2015-11-10
IL204539A (en) 2014-09-30
CR11520A (es) 2010-12-08
ES2535633T3 (es) 2015-05-13
JP5710262B2 (ja) 2015-04-30
CA2705873A1 (en) 2009-05-28
ECSP10010287A (es) 2010-08-31
AU2008328258B2 (en) 2013-09-26
EP2212423A2 (en) 2010-08-04
PL2212423T3 (pl) 2015-07-31
CN101868546A (zh) 2010-10-20
EP2212423B1 (en) 2015-02-11
BRPI0820578A2 (pt) 2015-06-16
HK1141314A1 (en) 2010-11-05

Similar Documents

Publication Publication Date Title
RU2010124616A (ru) Поксвирусные онколитические векторы
CA2705873A1 (en) Poxviral oncolytic vectors
JP2011504105A5 (enExample)
JP2019208511A (ja) 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
CN110157654B (zh) 一种纳豆芽孢杆菌重组菌及其构建方法与应用
PT2970934T (pt) Polipèptidos de valenceno sintase, moléculas de ácido nucleico que os codificam e suas utilizações
Wang et al. Draft genome sequence of Streptomyces globisporus C-1027, which produces an antitumor antibiotic consisting of a nine-membered enediyne with a chromoprotein
CA2943871C (en) POXVIRAL ONCOLYTIC VECTORS
CN107267477A (zh) 新穿心莲内酯糖基转移酶蛋白及其编码基因与应用
CN102382829B (zh) Fbxl15蛋白抑制剂以及它们的应用
KR20230119635A (ko) 백신 제조를 위한 효모 플랫폼
Von Itzstein et al. Anti-infectives Overview: The development of potential anti-influenza drugs
Coradin et al. Silicon in the photosynthetic lineages: molecular mechanisms for uptake and deposition
Douglass Molecular and evolutionary analysis of a gene conserved in most Orthopoxviruses
HK1230971B (en) Poxviral oncolytic vectors